Panbela Therapeutics, Inc. (PBLA)

Panbela Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Sep 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Selling, General & Admin	4.35	5.03	6.04	4.59	3.25	1.97
Research & Development	24.68	20.61	10.31	5.42	2.51	2.35
Operating Expenses	29.04	25.65	16.36	10.01	5.75	4.32
Operating Income	-29.04	-25.65	-16.36	-10.01	-5.75	-4.32
Interest Expense	-0.64	-0.32	-0.29	-0.01	-0.02	-2.19
Interest & Investment Income	0.01	0.12	0.01	0	-	-
Currency Exchange Gain (Loss)	0.83	-	-0.68	-0.6	0.61	-0.1
Other Non Operating Income (Expenses)	-0.01	-0.01	-	-	-	-
EBT Excluding Unusual Items	-28.85	-25.85	-17.31	-10.62	-5.17	-6.62
Gain (Loss) on Sale of Assets	0.78	0.4	-	-	-	-
Other Unusual Items	-	-	-	-	0.1	-
Pretax Income	-28.07	-25.45	-35.05	-10.62	-5.06	-6.62
Income Tax Expense	-0.16	-0.19	-0.12	-0.49	-0.3	-0.42
Net Income	-27.91	-25.26	-34.93	-10.14	-4.77	-6.2
Preferred Dividends & Other Adjustments	9.14	9.14	-	-	-	-
Net Income to Common	-37.05	-34.4	-34.93	-10.14	-4.77	-6.2
Shares Outstanding (Basic)	3	0	-	-	-	-
Shares Outstanding (Diluted)	3	0	-	-	-	-
EPS (Basic)	-11.31	-316.52	-	-	-	-
EPS (Diluted)	-11.31	-316.52	-	-	-	-
Free Cash Flow	-15.57	-25.25	-15.28	-7.25	-3.85	-2.74
Free Cash Flow Per Share	-4.75	-232.30	-	-	-	-
EBIT	-29.04	-25.65	-16.36	-10.01	-5.75	-4.32

Source: S&P Global Market Intelligence. Standard template. Financial Sources.